Delivering Corticosteroid Treatment for Patients With Uveitis-associated Macular Edema

Tuesday, August 20, 2024, 12:00 AM - Tuesday, August 19, 2025, 11:00 PM

This program will be 1 credit hour and the intended audience is retina specialists and comprehensive ophthalmologists. The program is a round table discussion among three experts focusing on ME secondary to noninfectious uveitis, the need to treat this condition promptly and aggressively, clinical results that have been obtained with the delivery of corticosteroids to the SCS, and best practices for injection and patient monitoring. Injection technique and efficacy and safety outcomes from clinical cases will be used to place the discussions in a real-world context.

Presented by:

• David Eichenbaum, MD, FASRS, partner and Director of Research at Retina Vitreous Associates of Florida in Tampa, FL.

• Sunil Srivastava, MD, uveitis and vitreoretinal specialist at the Cole Eye Institute at the Cleveland Clinic in Cleveland, OH.
  

Faculty Disclosures:

Dr. Eichenbaum states that he has received grant/research support from 4DMT, Alkahest, Annexon, AsclepiX, Bayer, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Iveric Bio, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Opthea, Recens Medical, Regeneron, Regenxbio, and Unity. He served as a consultant for Alimera, Allergan, Apellis, Bausch + Lomb, Coherus, Crinetics, DORC, EyePoint, Genentech, Gyroscope, Iveric Bio, KKR, Kodiak, Novartis, Opthea, Outlook, Recens Medical, Regeneron, Regenxbio, ReVive, US Retina, and Vial. He served on speaker’s bureaus for Allergan, Apellis, Bausch + Lomb, Bayer, DORC, EyePoint, Genentech, and Novartis. He owns stocks in Boston Image Reading Center, Clearside, Hemera Biosciences, Network
Eye, Outlook, ReVive, and US Retina.

Dr. Srivastava states that he has received grant/research support from Bausch + Lomb, Eyepoint, Eyevensys, and
Regeneron. He has served as a consultant for Bausch + Lomb, Eyepoint, Eyevensys, jCyte, Novartis, and Zeiss.

No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance Certificate (1.00 hours)

1. Summarize risk factors for the development of NIU and associated ME as well as evidence supporting the need to promptly treat these conditions.
2. Critically review drug delivery routes used in the treatment of uveitic ME and other ocular diseases, including their benefits and challenges.
3. Interpret results of key trials examining SCS injections for the treatment of ocular diseases, particularly uveitic ME, and how new data may eventually influence practice.
4. Describe proper techniques for SCS injection, solutions to common treatment challenges, and best practices for patient education and monitoring.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Candeo Clinical/Science Communications, LLC.. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Florida College of Medicine designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 
For CME general questions, please contact
Email: [email protected]

Mitigation of Relevant Financial Relationships

University of Florida College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control a CME activity's content, including faculty, planners, reviewers, and/or others, must disclose all financial relationships with ineligible companies (commercial interests). Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure. All relevant financial relationships have been mitigated.